|Articles|June 26, 2011

Sulfonylurea monotherapy ups CVD risk vs. metformin in older diabetics

Older patients started on oral antidiabetic therapy with a sulfonylurea have significantly higher risk for cardiovascular disease (CVD) events than patients started on metformin.

Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.

Subscribe Now!

Latest CME

Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Video

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

Trending on Medical Economics

28 states reject the CDC’s new childhood vaccine schedule, KFF finds

Sleep doctor convicted in insurer fraud, tax evasion; most commercially insured patients now live with chronic disease; the most anticipated drug launches of 2026 – Morning Medical Update

Sulfonylurea monotherapy ups CVD risk vs. metformin in older diabetics

Newsletter

Latest CME

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Trending on Medical Economics

28 states reject the CDC’s new childhood vaccine schedule, KFF finds

Sleep doctor convicted in insurer fraud, tax evasion; most commercially insured patients now live with chronic disease; the most anticipated drug launches of 2026 – Morning Medical Update

Osteopathic medical education: Real-world effects in Pikeville, Kentucky

GE HealthCare wins FDA clearance for Allia Moveo interventional imaging system

Why physicians must be able to say no and why health systems must let them